Paul B.  Manning net worth and biography

Paul Manning Biography and Net Worth

Director of Candel Therapeutics

Paul B. Manning is the president and CEO of PBM Capital Group based in Charlottesville, VA. An entrepreneur with 30 years of experience in the healthcare industry, in 2010 Paul founded PBM Capital Group, a private equity investment firm in the business of investing in health care and life-science related companies. Paul directs all investment decisions and sits on the Board of Directors for many of PBM Capital’s investments including: Avexis (NASDAQ:AVXS), Dova Pharmaceuticals, Verrica Pharmaceuticals, and PBM Pharmaceuticals.

Paul has successfully founded several companies that developed and distributed prescription and over the counter products to major chains in the United States. In 1997, Paul founded PBM Products, which became the largest private label producer of infant formula and baby/toddler food in the world. PBM Products was sold to Perrigo Corporation in 2010. Paul served on Perrigo Corporation’s Board of Directors after the sale.

Paul is an active member of the University of Virginia community, having served on the Board of UVA Strategic Planning Committee, the Board of UVA Health Foundation, and the Board of the President’s Advisory Committee. He graduated from the University of Massachusetts with a B.S. in Microbiology. He was named Virginia Entrepreneur of the Year by Ernst and Young in 2002. Paul has been married for 34 years to his wife Diane and has 3 children, Bradford, Kaity and Bryan.

What is Paul B. Manning's net worth?

The estimated net worth of Paul B. Manning is at least $17.61 million as of November 25th, 2025. Mr. Manning owns 3,348,372 shares of Candel Therapeutics stock worth more than $17,612,437 as of December 5th. This net worth estimate does not reflect any other assets that Mr. Manning may own. Learn More about Paul B. Manning's net worth.

How do I contact Paul B. Manning?

The corporate mailing address for Mr. Manning and other Candel Therapeutics executives is , , . Candel Therapeutics can also be reached via phone at 617-916-5445 and via email at [email protected]. Learn More on Paul B. Manning's contact information.

Has Paul B. Manning been buying or selling shares of Candel Therapeutics?

Paul B. Manning has not been actively trading shares of Candel Therapeutics within the last three months. Most recently, on Monday, December 16th, Paul B. Manning bought 1,250,000 shares of Candel Therapeutics stock. The stock was acquired at an average cost of $6.00 per share, with a total value of $7,500,000.00. Following the completion of the transaction, the director now directly owns 1,303,752 shares of the company's stock, valued at $7,822,512. Learn More on Paul B. Manning's trading history.

Who are Candel Therapeutics' active insiders?

Candel Therapeutics' insider roster includes Francesca Barone (Chief Scientific Officer), Paul Manning (Director), William Nichols (Chief Medical Officer), Charles Schoch (CFO), and Seshu Tyagarajan (CTO). Learn More on Candel Therapeutics' active insiders.

Are insiders buying or selling shares of Candel Therapeutics?

During the last twelve months, Candel Therapeutics insiders bought shares 1 times. They purchased a total of 1,250,000 shares worth more than $7,500,000.00. During the last twelve months, insiders at the sold shares 7 times. They sold a total of 79,525 shares worth more than $644,010.84. The most recent insider tranaction occured on July, 28th when insider William Garrett Nichols sold 937 shares worth more than $6,540.26. Insiders at Candel Therapeutics own 16.6% of the company. Learn More about insider trades at Candel Therapeutics.

Information on this page was last updated on 7/28/2025.

Paul B. Manning Insider Trading History at Candel Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/16/2024Buy1,250,000$6.00$7,500,000.001,303,752View SEC Filing Icon  
See Full Table

Paul B. Manning Buying and Selling Activity at Candel Therapeutics

This chart shows Paul B Manning's buying and selling at Candel Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Candel Therapeutics Company Overview

Candel Therapeutics logo
Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. The company also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent high-grade glioma. It also develops the?enLIGHTEN Discovery Platform, a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts.
Read More

Today's Range

Now: $5.26
Low: $4.97
High: $5.32

50 Day Range

MA: $5.21
Low: $4.42
High: $6.55

2 Week Range

Now: $5.26
Low: $4.25
High: $14.60

Volume

1,381,428 shs

Average Volume

682,855 shs

Market Capitalization

$288.77 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A